The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Open accessAbstract
Manufacturing processes for therapeutic monoclonal antibodies (mAbs) have evolved tremendously since the first licensed mAb product in 1986. The rapid growth in product demand for mAbs triggered parallel efforts to increase production capacity through construction of large bulk manufacturing plants as well as improvements in cell culture processes to raise product titers. This combination has led to an excess of manufacturing capacity, and together with improvements in conventional purification technologies, promises nearly unlimited production capacity in the foreseeable future. The increase in titers has also led to a marked reduction in production costs, which could then become a relatively small fraction of sales price for future products which are sold at prices at or near current levels. The reduction of capacity and cost pressures for current state-of-the-art bulk production processes may shift the focus of process development efforts and have important implications for both plant design and product development strategies for both biopharmaceutical and contract manufacturing companies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Downstream processing of monoclonal antibodies—Application of platform approaches
Shukla, A. A., Hubbard, B., Tressel, T., Guhan, S., & Low, D. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.09.026 · Cited by 876
Quality by Design in Biopharmaceuticals
Yang, H. (2016) · doi:10.1201/9781315371726-7 · Cited by 543
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Future of antibody purification
Low, D., O’Leary, R., & Pujar, N. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.10.033 · Cited by 472
Process economics of industrial monoclonal antibody manufacture
Farid, S. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.037 · Cited by 389
The Development Factory: Unlocking the Potential of Process Innovation
Pisano, G. P. (1996) · Cited by 353
Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations
Kelley, B. (2007) · Biotechnology Progress · doi:10.1021/bp070117s · Cited by 337
Self-citationFahrner, R. L., Knudsen, H. L., Basey, C. D., Galan, W., Feuerhelm, D., Vanderlaan, M., & Blank, G. S. (2001) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2001.10648017 · Cited by 259
Therapeutic antibody expression technology
Chadd, H. E., & Chamow, S. M. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00198-1 · Cited by 204
Economic aspects of commercial manufacture of biopharmaceuticals
Werner, R. G. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.04.036 · Cited by 142
Harris, R. J., Murnane, A. A., Utter, S. L., Wagner, K. L., Cox, E. T., Polastri, G., Helder, J. C., & Sliwkowski, M. B. (1993) · Nature Biotechnology · doi:10.1038/nbt1193-1293 · Cited by 78
Biopharmaceutical Proteins: Opportunities and Challenges
Birch, J. R., & Onabanjo, E. O. (2005) · Humana Press eBooks · doi:10.1385/1-59259-922-2:001 · Cited by 37
Cited by
DNA Nanotechnology-Enabled Drug Delivery Systems
Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,118
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Metadata
- Authors
- Kelley, B.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 1
- Issue
- 5
- Pages
- 443-452
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2134238361
- Cited by
- 667
- References
- 13
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.